AU Patent

AU2014218414A1 — Use of an adrenal hormone-modifying agent

Assigned to Novartis AG · Expires 2014-09-18 · 12y expired

What this patent protects

H:\dxjrlnvlveroaRPorthl\D(CC\RBR\68583 _LDOC-28/08/ 2014 The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, 5 comprising administering to the subject a…

USPTO Abstract

H:\dxjrlnvlveroaRPorthl\D(CC\RBR\68583 _LDOC-28/08/ 2014 The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, 5 comprising administering to the subject a therapeutically effective amount of a compound represented by formula (1): wherein n is 1 or3; R is hydrogen or--C(O)N(Ra)(Rb) wherein Ra and Rb are independently -(C1-C4) alkyl, or -(Cl-C4) alkyl-(C5-C7) aryl, wherein each of Ra and Rb is optionally substituted by --(C1-C4) alkoxy; R1, R2, and R3, are independently hydrogen, halogen, cyano or --(C6-C10) aryl, wherein said --(C6-C10) aryl is optionally substituted by 10 halogen, with the proviso that no more than one of R1, R2, and R3 is hydrogen; and R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014218414A1
Jurisdiction
AU
Classification
Expires
2014-09-18
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.